DOCSLIB.ORG

Valeant Pharmaceuticals (Montreal, Quebec, with Offices in Mississauga

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Valeant Pharmaceuticals (Montreal, Quebec, with Offices in Mississauga Strategy Valeant Pharmaceuticals (Montreal, Quebec, with offices in Mississauga, Valeant's strategy is to acquire, develop, and commercialize new products through partnerships Ontario; founded 1989) especially in the areas of neurology and dermatology. Neurological products under development include Preparation question: How does Valeant’s medications for depression, schizophrenia, Parkinson's, business model differ from Apotex? and pain, as well as an epilepsy drug being researched Source: Hoovers, 2011-2013, updated 11/2014 through a partnership with GlaxoSmithKline. The company is looking to broaden its lineup especially as Valeant Pharmaceuticals International (ex-Biovail) is some of its older offerings, such as Wellbutrin XL Canada's largest publicly traded drugmaker. The (an extended-release multinational specialty pharmaceutical company version of GSK's antidepressant Wellbutrin) and Ultram specializes in developing, manufacturing, and marketing ER (a long-acting version of J&J's chronic pain drug neurological and dermatological treatments, with a Ultram), face increasing levels of generic competition as portfolio of branded prescription, branded generic, and their patents expire. OTC products. Products in its dermatology segment include genital herpes treatment Zovirax and acne Under the direction of chairman and chief executive J. treatment Acanya, while products in its neurology Michael Pearson, Valeant has made about 50 acquisitions segment include antidepressant Wellbutrin XL. Valeant of companies and assets since 2008. Its acquisition acquired Bausch + Lomb in 2013 to establish a strong footprint is diverse, with several purchases in the US, presence in ophthalmology as well. Canada, Brazil, Russia, and Australia. The company tends to mix larger acquisitions with smaller ones in order to Geographic Reach beef up its portfolio of treatments for central nervous With manufacturing sites in Canada, Mexico, Brazil, and system and skin diseases. Poland, product sales are made around the world. The US Mergers and Acquisitions market (including Puerto Rico) accounts for more than 55% of Valeant's annual revenues. The company has Valeant has embarked on an aggressive acquisition significant specialty and OTC medicine offerings in strategy that has grown the company's revenues Canada, Australia, and New Zealand, as well as a growing exponentially in recent years. The company closed a presence selling branded, generic, and OTC offerings in record number of purchases in 2011, leading to portions of Latin America, Europe, Southeast Asia, and a 108% revenue jump to some $2.5 billion attributed to South Africa. increased product sales in a widening number of global markets. The company also returned to profitability, Operations reporting a $160 million net income figure in 2011 after In addition to the core areas of central nervous system, dropping into the red in 2010 due to acquisition and dermatology, and ophthalmology, Valeant has integration expenses from the Valeant/Biovail merger. prescription offerings for cardiovascular and The company significantly strengthened its position in metabolic ailments. Valeant also has a handful of off- dermatology when it acquired US-based Medicis patent branded drugs, which it continues to sell but does Pharmaceutical for $2.6 billion in December 2012. The not actively promote. These drugs include Cardizem CD Medicis deal gives Valeant a formidable lineup of acne, (a controlled-release version of Cardizem), anxiety drug aesthetic injectable, and antiviral products, and it builds Ativan, and hypertension medication Vasotec. In addition upon prior acquisitions of Dermik and Ortho in 2011 to to branded drugs, Valeant makes generic formulations, cement Valeant's position as a leader in US dermatology. some of them generic versions of its own brands. Valeant's aggressive acquisition strategy has brought Sales and Marketing some failures along with successes, including a $5.7 Valeant sells its products through direct sales billion attempt to acquire fellow neurological representatives in the US and Canada, as well as through drugmaker Cephalon in 2011 and two unsolicited marketing partnerships and distributors in the US and offers ($314 million and $360 million) for ophthalmic international markets. For instance, Valeant sells top- therapies maker ISTA Pharmaceuticals. selling neurology drug Wellbutrin XL in the US, In 2013, Valeant completed an $8.7 billion deal ($4.5 while GlaxoSmithKline sells the product in international billion in cash and $4.2 billion in debt) to acquire Bausch markets. Customers include wholesale drug distributors, + Lomb from Warburg Pincus private equity. B&L’s hospitals, physicians, and pharmacies. Valeant's lines include contact lenses, lens care, and drugs and marketing programs often include direct mailings, trade implants for eye diseases. B&L had 2013 sales of $3.1 magazine ads, and event exhibits and sponsorships. billion, with -3% net profit and 11,000 employees. The deal gives Valeant a leading position in the 1 ophthalmology market and boosts its operations in the efforts to focus on CNS operations, Melnyk (who was medical device industry. Valeant aims to leverage the then the company's largest shareholder with about 18% of brand in emerging markets; its existing eye care products stock) fought against the new plan and waged an and pharmaceuticals are being merged into the Bausch + unsuccessful proxy fight aimed at returning the company Lomb division following the purchase. to its original focus on difficult-to-manufacture generics and brand extensions. In 2010 Melnyk gave up his fight Ownership and sold off his holdings in the company he had founded. Investors with significant stakes in Valeant include Valeant (then named Biovail) bought the US marketing Ruane, Cuniff & Goldfarb (12%) and FMR (10%). rights for top selling neurology drug Wellbutrin XL back History from GSK in 2009, reversing its previous strategy of solely relying on partnerships to sell its drugs in the US. In 2010 the company, then named Biovail Corporation, (GSK continued to handle international marketing of the acquired the former Valeant Pharmaceuticals for $3.3 drug.) The $510 million asset purchase fed the company's billion and took on the Valeant name. The purchase strategy of focusing on CNS therapies, and the firm hoped widened its neurological offerings, as well as its that off-patent sales of Wellbutrin XL would generate dermatology and over-the-counter (OTC) lines and its significant cash to support its R&D programs. The international distribution network. Both companies were deal also gave Valeant the right to produce an authorized already undergoing restructuring efforts to focus on core generic version of Wellbutrin XL. The company offerings, and the new Valeant further cut operational also launched its new depression therapy, Aplenzin, expenses through post-merger integration efforts, through a marketing arrangement with French including a 25% reduction of the combined workforce. drugmaker Sanofi in 2009. Valeant and Biovail combined operations in a reverse- In mid-2009 Valeant acquired the worldwide rights to the merger transaction. Valeant had historically been focused entire portfolio of tetrabenazine products (including on developing improved versions of existing drugs using international Xenazine rights) from Cambridge its oral drug-delivery technologies; however, due Laboratories for $230 million. It also gained several early to increased competition in the drug-delivery stage CNS drug development programs through the deal, technologies marketplace, the company began shifting its including a tetrabenazine program for the treatment of focus to proprietary CNS therapies. Both Ultram ER and Tourette syndrome. The company netted more CNS drugs Cardizem LA (a long-acting version of Sanofi's blood in 2010 with the purchase of certain compounds pressure therapy Cardizem) started facing competition from Cortex Pharmaceuticals. from generic versions in 2009 and 2010. In 2010 Valeant sold its noncore contract research The combined company retained the Biovail division to Lambda Therapeutic Research for $6 million. headquarters in Canada, as well as the Biovail corporate structure, but Michael Pearson, CEO of the old Valeant, took the reins of the new Valeant (replacing former Biovail CEO Bill Wells). [Note; this was one of Recent activity: 2014 the earlier tax inversion deals, which have recently Valeant leadership has said that its goal is to become the become controversial in the US]. world’s largest specialty drug company, with sales of at In addition to meeting growth targets, the company's least $20 billion. It plans to achieve this target primarily name change to Valeant following the merger could also via acquisitions. signify a desire to disassociate itself Throughout 2014, Valeant has been engaged in a highly with some past troubles associated with the Biovail name. public attempt to take over Allergan, Inc., in partnership While operating as Biovail, the company and some of its with Pershing Share Capital Management, with a hostile former executives were charged with accounting fraud in takeover offer worth more than $50 billion. Allergan, with 2008 by the SEC, which claimed that the company misled 2013 sales of $6.3 billion, net profit of 16%, and 11,400 investors over earnings and losses. The company paid a employees, is a US-based specialty drug company with fine to settle the SEC charges; it also paid fines to settle sales in ophthalmics, dermatology, neuroscience,
Load more

Recommended publications
  • Inside Valeant's Fall
    March 29, 2017 ROB MAGAZINE Inside Valeant’s fall How an analyst, a hedge fund manager and a journalist exposed the fatal flaws in CEO Michael Pearson’s strategy and ended a drug-fuelled capital markets rampage CHARLES WILLIAMS BRUCE LIVESEY SPECIAL TO THE GLOBE AND MAILLAST UPDATED: WEDNESDAY, MAR. 29, 2017 9:49AM EDT U.S. Senator Elizabeth Warren is renowned for pillorying captains of industry when the opportunity presents itself. Such an occasion arose one cool, overcast day in April of last year, when J. Michael Pearson sat in front of a group of senators in a wood-panelled chamber on Capitol Hill in Washington, D.C. As the recently fired (but still acting) CEO of Laval, Quebec-based Valeant Pharmaceuticals International Inc., Pearson was appearing before the Senate’s Special Committee on Aging to answer for Valeant’s penchant for jacking up drug prices to unholy levels. The room was packed with aides, reporters and anxious businesspeople. Warren, a Democrat from Massachusetts, is a former Harvard law professor with a rapier intelligence and a willingness to be blunt. At one point she drilled down on Valeant’s use of “patient assistance programs.” Warren felt that such programs—which typically cover some or all of a patient’s co-payment—were a cunning way to keep consumers using overpriced drugs after the company hiked prices. “What is the return to Valeant on the money that you’re currently putting into the patient assistance program?” Warren demanded pointedly. Pearson, a fleshy 57-year-old with grey hair and a long puffy face, was looking rather whipped despite his natty charcoal suit and burgundy tie.
    [Show full text]
  • Journal Title Subject Area American Journal of Health-System Pharmacy : AJHP Medicine -- Pharmacy and Materia Medica A.I.H.P
    Journal Title Subject Area American Journal of Health-System Pharmacy : AJHP Medicine -- Pharmacy and materia medica A.I.H.P. Notes Medicine -- Pharmacy and materia medica aaiPharma, Inc. SWOT analysis Medicine -- Therapeutics. Pharmacology AAPS journal Medicine -- Pharmacy and materia medica AAPS pharmscitech Medicine -- Pharmacy and materia medica Abbott laboratories SWOT analysis Medicine -- Therapeutics. Pharmacology Abgenix, Inc. SWOT analysis Medicine -- Therapeutics. Pharmacology Able laboratories SWOT analysis Medicine -- Therapeutics. Pharmacology Academic Pharmacy Now Medicine -- Pharmacy and materia medica Accredo Health, Inc. SWOT Analysis Medicine -- Therapeutics. Pharmacology ACS Medicinal Chemistry Letters Medicine -- Pharmacy and materia medica Acta Facultatis Pharmaceuticae Universitatis Comenianae Medicine -- Pharmacy and materia medica Acta Pharmaceutica Medicine -- Pharmacy and materia medica Acta Pharmacologica Sinica Medicine -- Therapeutics. Pharmacology Medicine -- Therapeutics. Pharmacology -- Physical Acta Radiologica Short Reports medicine. Physical therapy Actu Labo Medicine -- Pharmacy and materia medica Medicine -- Therapeutics. Pharmacology -- Other Acupuncture & Electro-Therapeutics Research therapeutic procedures Acupuncture in Medicine Medicine -- Therapeutics. Pharmacology Acupuncture: Review and Analysis of Reports on Controlled Clinical Trials Medicine -- Therapeutics. Pharmacology Adolescent Health, Medicine and Therapeutics Medicine -- Therapeutics. Pharmacology AdvancePCS, Inc. SWOT Analysis Medicine
    [Show full text]
  • 9155 Biovail Q1 Prepress
    Q1 First Quarter Report Biovail Corporation 2001 Interim Report Dear fellow shareholders: I am pleased to report that Biovail has started the year 2001 with record first quarter financial results. These results reflect a major product line acquisition along with a number of additional milestones as the Company continues to evolve into a major fully-integrated North American pharmaceutical operation. Cardizem® acquisition At the beginning of the quarter, Biovail acquired the North American rights to the entire Cardizem® line of diltiazem products from Aventis Pharmaceuticals Inc. Cardizem® is a market leading brand of calcium channel blockers for the treatment of hypertension and angina. Total U.S. sales of calcium channel blockers in 2000 exceeded $3.5 billion. Cardizem® CD was the best selling diltiazem product in the U.S. last year with over 13 million prescriptions. Other products in the line include Cardizem®, Cardizem® SR and Cardizem® injectables. The acquisition of this significant product line is expected to add over $150 million in incremental revenue in 2001. The acquisition of the Cardizem® line also allows Biovail to add value to its new improved once-daily diltiazem product, currently undergoing studies to support superior marketing claims. This new product, which has already received FDA approval, will likely be launched as Cardizem® XL. This new product will offer measurable therapeutic advantages. Biovail expects to launch Cardizem® XL mid 2002. U.S. sales operations The integration of DJ Pharma, the U.S. sales operation acquired by Biovail in 2000, was completed during the quarter. The Company’s new U.S. sales operation, renamed Biovail Pharmaceuticals, will be based in Raleigh, North Carolina.
    [Show full text]
  • Biovail Corporation U.S.$300,000,000 6.75% Convertible Subordinated Preferred Equivalent Debentures Due March 31, 2025 (U.S.$50 Principal Amount Per Security)
    Prospectus March 17, 2000 Biovail Corporation U.S.$300,000,000 6.75% Convertible Subordinated Preferred Equivalent Debentures due March 31, 2025 (U.S.$50 principal amount per security) The Company: · Interest Deferral Option: we have the right, at any time · We are an international, fully-integrated pharmaceutical and from time to time, to defer payment of interest on company that specializes in the development, the Securities by extending the interest payment period manufacture, marketing and licensing of drugs utilizing up to 20 consecutive quarters. advanced controlled-release, rapid dissolve, enhanced · Conversion Price: U.S.$60.675 per common share (equal absorption and taste masking technologies. to an initial conversion ratio of .8241 common shares per Security, subject to adjustment). · Biovail Corporation 2488 Dunwin Drive · Conversion Right: convertible at any time into our Mississauga, Ontario common shares at the applicable conversion price. Canada L5L 1J9 · Optional Redemption: beginning on March 31, 2003, we (416) 285-6000 may redeem the Securities, in whole or in part, at any time (except during an interest deferral period) at the · NYSE and TSE symbol for our common shares: BVF redemption prices stated herein, plus accrued and unpaid The Offering: interest. · Special Redemption: we may redeem the Securities, in · The Convertible Subordinated Preferred Equivalent whole or in part, at a redemption price of 106.75%, plus Debentures (the ``Securities'') are convertible accrued and unpaid interest, at any time and from time subordinated debentures bearing an interest rate, payable to time (except during an interest deferral period) prior in U.S. dollars, of 6.75% per year.
    [Show full text]
  • Complaint in This Matter
    MARK K. SCHONFELD REGIONAL DIRECTOR Attorneys for Plaintiff SECURITIES AND EXCHANGE COMMISSION New York Regional Office 3 World Financial Center New York, NY 10281 (212) 336-1120 UNITED STATES DISTRICT COURT -SOUTHERNDISTRICT OF NEW YORK SECURITIES AND EXCHANGE COMMISSION, Plaintiff, 08 Civ. - ECF CASE BIOVAIL CORPORATION, EUGENE N. MELNYK, BRIAN CROMBIE, JOHN MISZUK, and COMPLAINT KENNETH G. HOWLING, Defendants. Plaintiff Securities and Exchange Commission, for its Complaint against Defendants Biovail Corporation ("Biovail" or the "Company"), Eugene N. Melnyk, Brian Crombie, John Miszuk and Kenneth G. Howling (collectively, "Defendants"), alleges as follows: SUMMARY OF ALLEGATIONS 1. This case involves chronic fraudulent conduct - including financial reporting fraud and other intentional public misrepresentations -by Biovail Corporation, a Canadian pharmaceutical company whose common stock is traded on the New York and Toronto stock exchanges. Obsessed with meeting quarterly and annual earnings guidance, Biovail's executives repeatedly overstated earnings and hid losses in order to deceive investors and create the appearance of achieving that goal. And, when it ultimately became impossible to continue to conceal the Company's poor performance, Biovail actively misled investors and analysts as to its cause. This corrupt strategy was employed by Biovail's most senior officers: Eugene Melnyk, former chairman and chief executive officer; Brian Crombie, former chief financial officer; Jo,hn Miszuk, vice president, controller, .and assistant
    [Show full text]
  • ACADIA PHARMACEUTICALS 2012 ANNUAL REPORT » COMPOUND/PROGRAM PIMAVANSERIN » COMMERCIALIZATION RIGHTS » INDICATION { Phase 3 } PARKINSON’S DISEASE ACADIA PSYCHOSIS
    ACADIA PHARMACEUTICALS 2012 ANNUAL REPORT » COMPOUND/PROGRAM PIMAVANSERIN » COMMERCIALIZATION RIGHTS » INDICATION { Phase 3 } PARKINSON’S DISEASE ACADIA PSYCHOSIS » COMPOUND/PROGRAM PIMAVANSERIN » COMMERCIALIZATION RIGHTS » INDICATION { Phase 2 } SCHIZOPHRENIA ACADIA » COMPOUND/PROGRAM PIMAVANSERIN » COMMERCIALIZATION » INDICATION { Phase 2 } RIGHTS ALZHEIMER’S DISEASE ACADIA PSYCHOSIS » ABOUT ACADIA PHARMACEUTICALS We are a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. Our pipeline of product candidates is led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson’s disease psychosis. Pimavanserin also has the potential to address a range of other neurological and psychiatric disorders, including Alzheimer’s disease psychosis and schizophrenia, which also are underserved by currently marketed antipsychotic drugs. » DEAR FELLOW STOCKHOLDERS 2012 was a breakthrough year for ACADIA culminating with the impressive results from our pivotal Phase III -020 Study with pimavanserin for Parkinson’s disease psychosis (PDP) and our successful financing. These important achievements, coupled with our April 2013 announcement of an expedited path to NDA filing, provide a strong foundation for rapidly advancing pimavanserin to registration in PDP and strategically expanding the pimavanserin program into other important neurological and psychiatric indications. I believe that we are now well positioned to execute on our strategy of building a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies that improve the lives of patients with neurological and related central nervous system disorders. Advancing our Phase III PDP Program to Registration Today, there are no drugs approved in the United States to treat PDP, a debilitating disorder that develops in up to 60 percent of Parkinson’s patients.
    [Show full text]
  • Biovail Ann.02 Cover Biov1008
    biovail ann’02 cover biov1008 5/20/03 10:02 AM Page 1 Biovail 2002 Annual Report Making medicine easier to take Biovail 2002 Annual Report 7150 Mississauga Road, Mississauga, Ontario L5N 8M5 www.biovail.com Making medicine easier to take biovail ann’02 cover biov1008 5/20/03 10:02 AM Page 2 Corporate Profile Biovail Corporation is an international fully integrated pharmaceutical company specializing in the development, manufacture, sale and marketing of medications for the treatment of chronic medical conditions. Biovail has a number of proprietary drug Shareholder Information delivery technologies that it applies to brand name drugs to produce enhanced versions. >> While Biovail continually explores all therapeutic areas, the company’s main therapeutic areas are cardiovascular, central nervous system and pain management. Biovail currently markets more than 20 products in North America and a number of products throughout 55 other countries, both directly and through strategic marketing partnerships. Biovail’s direct marketing efforts in North America are supported by an extensive U.S. and Canadian sales force of more than 650 sales professionals. >> Biovail maintains an active drug development pipeline and its proprietary technology platforms are currently being applied to more than 30 promising pharmaceutical products. >> Biovail Corporation, with more than HEAD OFFICE AUDITORS HOW TO REACH US FOR MORE INFORMATION 1,800 employees worldwide, trades on the New York Stock Exchange and the Toronto Stock Exchange under the symbol BVF. Biovail Corporation Ernst & Young LLP 7150 Mississauga Road Chartered Accountants For additional copies of this report, Mississauga, Ontario Toronto, Canada the annual report on Form 20-F as Canada L5N 8M5 filed with the United States Securities and Exchange Commission, quarterly LEGAL COUNSEL reports or for further information, MANUFACTURING FACILITIES Osler, Hoskin & Harcourt LLP please contact Investor Relations.
    [Show full text]
  • In the Matter of Biovail Corporation, Eugene N. Melnyk, Brian H
    Ontario Commission des P.O. Box 55, 19th Floor CP 55, 19e étage Securities valeurs mobilières 20 Queen Street West 20, rue queen ouest Commission de l’Ontario Toronto ON M5H 3S8 Toronto ON M5H 3S8 IN THE MATTER OF THE SECURITIES ACT, R.S.O. 1990, c. S.5, as amended -AND- IN THE MATTER OF BIOVAIL CORPORATION, EUGENE N. MELNYK, BRIAN H. CROMBIE, JOHN R. MISZUK and KENNETH G. HOWLING REASONS AND DECISION Hearing: March 4, 5, 6, 9, 10, 11, 12, 30 and 31, 2009 April 1, 2, 3, 6, 7, 8, 9, 13, 14, 15, 22, 24, 25 and 26, 2009 June 22, 24, 25 and 26, 2009 Decision: September 30, 2010 Panel: James E. A. Turner - Vice-Chair and Chair of the Panel David L. Knight, F.C.A. - Commissioner Paulette L. Kennedy - Commissioner Counsel: Kent E. Thomson - For Eugene N. Melnyk James Doris Sean Campbell Johanna Superina - For Staff of the Ontario Securities Alexandra Clark Commission Caitlin Sainsbury TABLE OF CONTENTS I. INTRODUCTION..............................................................................................................................................1 II. BACKGROUND ................................................................................................................................................2 A. THE BIOVAIL PARTICIPANTS IN THE HEARING ...........................................................................................2 (i) Biovail and Biovail Laboratories Incorporated ..................................................................................2 (ii) Melnyk ...............................................................................................................................................2
    [Show full text]
  • ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification Number) 11085 Torreyana Road, Suite 100 San Diego, California 92121 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (858) 558-2871 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, par value $0.0001 per share The NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • History Valeant Pharmaceuticals International, Inc. Introduction
    Valeant Pharmaceuticals International, Inc. Jason Arnold, Kari Froehlich, Mat McBride, Stanley Parker, Ann Utterback, Robin Chapman, Gail Christian / Arizona State University Introduction significant restructuring efforts before and resulting from the merger, an important question is whether Valeant Pharmaceuticals International, Inc. pro- the changes will yield the benefits promised to motes itself as a multinational specialty pharma- shareholders and enable the firm to compete more ceutical company with a diverse product portfolio effectively. The answers to these questions and oth- focusing on branded pharmaceuticals, branded ers appearing in this case will influence Valeant’s and unbranded generics, and over-the-counter future success. (OTC) products specializing in neurology and der- matology.1 Product sales focus on North America, Central Europe, Mexico, Brazil, and Australia, with History manufacturing sites in Canada, Brazil, Poland, and Valeant Pharmaceuticals was founded in 1960 by 2 Mexico. Milan Panic, a Yugoslavian defector. The com- In his 2006 message to shareholders, Timothy pany started in California and was originally called C. Tyson, then president and chief executive officer, International Chemical & Nuclear Corp. (ICN). reflected, “In many ways, 2006 was a life-changing Panic ran the company for 43 years.5 Initially, the year for Valeant Pharmaceuticals. It was a challeng- company’s primary business involved chemical and ing year—one that certainly stretched us and tested drug sales, but it grew through acquisitions of small our resolve.”3 That was the year that Valeant lost drug companies. In 1963, the company launched its chairman Robert W. O’Leary to cancer. Valeant its IPO.6 would face a new set of challenges in the fall of 2010, In 1970, ICN scientists discovered ribavirin and when it merged with Canada’s Biovail Corporation.
    [Show full text]
  • Bausch Health 2019 Annual Report
    BAUSCH HEALTH COMPANIES INC. Pivot to BAUSCH HEALTH COMPANIES INC. Offense 2019 ANNUAL REPORT 2019 ANNUAL REPORT Quality Customer Health Care Focused Our Vision Outcomes To Be Your Trusted Core Health Care Partner Principles CORE VALUES • Accountability People Innovation • Agility • Courage • Integrity • Teamwork • Results Orientation Effciency Our Mission Improving People’s Lives With Our Health Care Products COMPANY OVERVIEW We are a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of branded, generic and branded generic pharmaceuticals, medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) and over-the- counter (OTC) products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com. FORWARD-LOOKING STATEMENTS This annual report contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, “forward-looking statements”), including, but not limited to, statements regarding the Company’s future prospects and performance, anticipated product launches and geographic expansion and the expected timing of such launches and expansion, anticipated timing for the submission of certain of our pipeline products and R&D programs, anticipated advances in our development programs
    [Show full text]
  • Valeant Pharmaceuticals International, Inc
    VALEANT PHARMACEUTICALS INTERNATIONAL, INC. FORM 6-K (Report of Foreign Issuer) Filed 07/28/99 for the Period Ending 07/01/99 Telephone 514-744-6792 CIK 0000885590 Symbol VRX SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. BIOVAIL CORP INTERNATIONAL FORM 6-K (Report of Foreign Issuer) Filed 7/28/1999 For Period Ending 7/1/1999 Address 7150 MISSISSAUGA ROAD MISSISSAUGA ONTARIO, 00000 Telephone 905 286-3000 CIK 0000885590 Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 1999 001-11145 (Commission File No.) BIOVAIL CORPORATION INTERNATIONAL (Translation of registrant's name into English) 2488 Dunwin Drive, Mississauga, Ontario L5L 1J9, Canada (Address of principal executive offices and zip code) Registrant's Telephone Number, including area code: (416) 285-6000 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F_X_ Form 40-F ___ Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ___ No _X_ Exhibit 99 (a) CONTACT: Eugene Melnyk Chairman of the Board Robert Podruzny President (416) 285-6000 Web Page: www.biovail.com Investor Relations e-mail: [email protected] FOR IMMEDIATE RELEASE: *BIOVAIL TO ACQUIRE FUISZ TECHNOLOGIES* Acquisition to Expand Biovail's Pipeline of Products and Delivery Platforms.
    [Show full text]